Nektar Therapeutics Shares Initial Preclinical Findings for its New CSF-1 Program, NKTR-422, at the 2024 ACR Convergence.

Tisotumab Vedotin-tftv is an antibody-drug conjugate (ADC) developed by Genmab and Seagen, a protein that is overexpressed in various solid tumors.

Icotrokinra provided impressive skin improvement and proven safety as a once daily tablet in Phase 3 results.

Tofersen, developed by Biogen in collaboration with Ionis Pharmaceuticals, is an antisense oligonucleotide that targets the superoxide dismutase 1 (SOD1) mRNA.

Neurizon Therapeutics Limited is excited to report favorable outcomes from a preclinical evaluation of its primary candidate, NUZ-001.

Virion Therapeutics announces initial clinical responses from VRON-0200, a new checkpoint modifier aimed at achieving functional cure for HBV, during The Liver Meeting® at AASLD.

UCB has gained FDA approval for BIMZELX® (bimekizumab-bkzx), making it the first IL-17A and IL-17F blocker for adults suffering from moderate to severe hidradenitis suppurativa.

Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with HFpEF and obesity.

Adicet has started recruiting participants for the Phase 1 clinical trial of ADI-270 in patients with metastatic or advanced clear cell renal cell carcinoma.

Pharmanovia enters a new licensing deal with Lindis Biotech to market Catumaxomab for the rare disorder malignant ascites.

Merck has launched a Phase 3 trial for subcutaneous pembrolizumab combined with berahyaluronidase alfa, achieving its primary goals.

Otsuka shared new information about Sibeprenlimab, an experimental monoclonal antibody aimed at treating IgA nephropathy in adults.